Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/30—Oxygen or sulfur atoms
  • C07D233/32—One oxygen atom
  • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/68—Halogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
  • C07D237/30—Phthalazines
  • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
  • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• the present invention relates to novel beta-agonists of the general formula (I)
• radicals R 1 to R 7 have the meanings mentioned in the claims and the description, their tautomers, their enantiomers, their diastereomers, their mixtures, their prodrugs and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, Process for the preparation of these compounds and their use as medicaments.
• Beta-3 receptor agonists are known to have a marked effect on lipolysis, thermogenesis and serum glucose levels in animal models of type II diabetes (Arch JR beta (3) adrenoceptor agonists: potential, pitfalls and progress, Eur J Pharmacol., 2002 Apr 12; 440 (2-3): 99-107). Structurally similar compounds as well as their broncholytic, spasmolytic and antiallergic action have been disclosed for example in DE 2833140.
• compounds of the general formula (I) in which the radicals R 1 to R 7 have the meanings mentioned below act as selective beta-3 agonists.
• the compounds of the invention can be used to treat diseases associated with the stimulation of beta-3 receptors.
• the present invention therefore relates to compounds of the general formula (I)
• R 1 is an optionally substituted aryl or heteroaryl group
• R 2 is an optionally substituted heteroaryl or heterocyclyl group, wherein R 2 contains at least one nitrogen atom
• R 3 and R 4 are each independently a hydrogen atom or an optionally substituted radical selected from the group consisting of Ci-Cs-alkyl, C 3 -C 6 - cycloalkyl, heterocyclyl, aryl and heteroaryl or R 3 and R 4 together have a 2- to 7-membered alkylene bridge,
• R 5 , R 6 and R 7 independently represent a hydrogen atom or a radical selected from the group consisting of optionally substituted C 1 -C 10 -alkyl, alkenyl, alkynyl, C 6 -C 10 -aryl, heterocyclyl, C 3 -C 8 -cycloalkyl , -NR 8 - (C 1 -C 5 -alkyl), -NR 8 - aryl, halogen, cyano, -NR 8 CO- (CC 5 -alkyl), -NR 8 CO-aryl, -NR 8 S0 2 - ( C 1 -C 5 alkyl), -NR 8 S0 2 -aryl, -C0 2 R 8 , -S0 2 R 8 , -CONHR 8 , -S0 2 NHR 8 and -OR 8 , wherein the abovementioned alkyl groups each substituted may be, and R 8 represents a hydrogen atom or a -CC 5 alky
• R 2 to R 7 have the abovementioned meaning
• R 1 represents an optionally substituted phenyl group.
• Another preferred subgroup relates to the compounds of the general
• R 1 and R 3 to R 7 have the abovementioned meaning
• R 2 is a radical selected from the group consisting of the optionally substituted radicals of the formulas:
• R 10 and R 10 is OH, NO 2 , CN, -OCHF 2 , -OCF 3 , -NH 2 ,, -NH-alkyl, -N (-alkyl) Alkyl, -NH-aryl, -N (-alkyl) -aryl, -NHCO-alkyl, -NHC0 2 -alkyl, -NHCO-aryl, -N (-alkyl) -CO-alkyl, -N (-alkyl) -CO-aryl, -NHSO 2 -alkyl, -NHSO 2 -aryl, -N (-alkyl) -SO 2 -alkyl, -N (-alkyl) -SO 2 -aryl, -CO 2 -alkyl, -SO 2 Alkyl, -SO 2 -aryl, -CONH-alkyl, -CONH
• R 1 and R 2 and R 5 to R 7 have the abovementioned meaning
• R 3 and R 4 independently of one another denote a hydrogen atom or a methyl or ethyl group or R 3 and R 4 together represent a 2- to 5-membered alkylene bridge.
• R 1 to R 4 have the abovementioned meaning
• R 5 , R 6 and R 7 are independently hydrogen, optionally substituted
• R 8 represents a hydrogen atom or a -CC 5 alkyl group.
• R 1 represents an optionally substituted by a halogen atom or a cyano or nitro group phenyl group
• R 2 is a radical selected from the group consisting of the optionally substituted radicals of the formulas:
• R 10 and R 10 is OH, NO 2) CN, -OCHF 2 , -OCF 3 , -NH 2 ,, -NH-alkyl, -N (-alkyl) Alkyl, -NH-aryl, -N (-alkyl) -aryl, -NHCO-alkyl, -NHC0 2 -alkyl, -NHCO-aryl, -N (-alkyl) CO-alkyl, -N (-alkyl) - CO-aryl, -NHSO 2 -alkyl, -NHSO 2 -aryl, -N (-alkyl) -SO 2 -alkyl, -N (-alkyl) -SO 2 -aryl, -CO 2 -alkyl, -SO 2 - Alkyl, -SO 2 -aryl, -CONH-alkyl, -CONH-aryl, -CONH-ary
• R 3 and R 4 are each independently a methyl or ethyl group or
• R 5 , R 6 and R 7 independently of one another each represent a hydrogen, fluorine or chlorine atom or a cyano, methoxy, methanesulfonylamino, methanesulfonyl, difluoromethoxy, trifluoromethoxy, difluoromethyl or trifluoromethyl group and
• R 9 is a hydrogen atom or an optionally substituted aryl or optionally substituted heteroaryl group.
• R 1 is optionally a fluorine, chlorine, bromine or iodine atom or a
• R 2 is a radical selected from the group consisting of the radicals of
• R 9 represents an optionally substituted by a fluorine atom or an amino, nitro, hydroxy or methoxy substituted phenyl or pyridyl group and where the abovementioned groups (i) to (vi) can each be substituted by one or two groups R 10 and R 10 is OH, NO 2 , CN, -OCHF 2, -OCF 3> -NH 2> -NH-alkyl, -N (alkyl) -alkyl, -NH-aryl, -N (alkyl) -aryl, -NHCO-alkyl, -NHC0 2 -alkyl, -NHCO-aryl, -N (-alkyl) -CO-alkyl, -N (-Alkyl) -CO-aryl, -NHSO 2 -alkyl, -NHSO 2 -aryl, -N (-alkyl) -SO 2 -alkyl, -N (-alkyl
• R 3 and R 4 independently of one another methyl or ethyl group or
• R 3 and R 4 together form an ethylene bridge
• R 5 , R 6 and R 7 independently of one another denote a hydrogen, fluorine or chlorine atom or a cyano, methoxy, methanesulfonylamino, methanesulfonyl, difluoromethoxy, trifluoromethoxy, difluoromethyl or trifluoromethyl group.
• R 1 is a phenyl group optionally substituted by a fluorine, chlorine, bromine or iodine atom or a cyano or nitro group
• R 2 is a radical selected from the group consisting of the radicals Formulas (i) - (vi):
• R 9 represents an optionally substituted by a fluorine atom or an amino, nitro, hydroxy or methoxy substituted phenyl or pyridyl group, and wherein the groups listed above (i) to (vi) each substituted by one or two groups R 10 R 10 can be OH, -NO 2 , -CN, -NH 2 , -I, -N (CH 3 ) 2 , -NHC0 2 CH 3 , -NHSO 2 CH 3 , -CC 3 -alkyl, -SO 2 N (CH 3 ) 2, -C0 2 H, benzyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, -CONHOH, tetrazol-5-yl, pyridinyl, methoxypyridinyl, optionally substituted by hydroxy, fluoro, methoxy, amino, nitro, dimethylamino, methylcarbonylamino , Methylsulfon
• R 3 and R 4 each represent a methyl or ethyl group or R 3 and R 4 together represent an ethylene bridge and R 5 , R 6 and R 7 each represent a hydrogen atom.
• R 1 is a phenyl group
• R 2 is a radical selected from the group consisting of the radicals of the formulas (i) - (iii) or (v): wherein R 9 represents an optionally substituted by a fluorine atom or an amino, nitro, hydroxy or methoxy substituted phenyl or pyridyl group, and wherein the groups listed above (i) to (iii) and (v) each by a group R 10 R 10 may be an iodo atom or a nitro, amino, methyl, carboxy, methoxycarbonyl, ethoxycarbonyl, pyridin-4-yl, pyridin-2-yl, 6-methoxypyridine-3 yl, thiophen-2-yl, 5-methyl-thiophen-2-yl, 3,5-dimethylisoxazol-4-yl, 1-acetyl-2-amino-propen-1-yl or a phenyl group in which the phenyl group, preferably in position 4, is replaced
• R 3 and R 4 each represent a methyl group
• R 5 , R 6 and R 7 each represent a hydrogen atom
• R 1 is a phenyl group
• R 2 is a radical of the formulas (ia) or (v):
• R 3 and R 4 each represent a methyl group
• R 5 , R 6 and R 7 each represent a hydrogen atom.
• Another object of the invention are compounds of general formula (I) for use as medicaments.
• Another object of the invention are compounds of general formula (I) for use as drugs with selective beta-3-agonistic action.
• Another object of the invention are compounds of general formula (I) for the manufacture of a medicament for the treatment and / or prevention of diseases associated with the stimulation of beta-3 receptors.
• Another object of the invention is a method of treatment and / or
• Another object of the invention is a pharmaceutical composition containing as active ingredient one or more compounds of general formula (I), optionally in combination with conventional excipients and / or carriers.
• Another object of the invention is a pharmaceutical composition containing as active ingredient one or more compounds of general formula (I) or their physiologically acceptable salts and one or more active substances selected from the group consisting of antidiabetics, inhibitors of protein tyrosine phosphatase 1, substances that one deregulated Glucose production in the liver, lipid-lowering drugs, cholesterol absorption inhibitors, HDL-increasing compounds, drugs for the treatment of obesity and modulators or stimulators of the adrenergic system via alpha 1 and alpha 2 as well as beta 1, beta 2 and beta 3 receptors.
• active substances selected from the group consisting of antidiabetics, inhibitors of protein tyrosine phosphatase 1, substances that one deregulated Glucose production in the liver, lipid-lowering drugs, cholesterol absorption inhibitors, HDL-increasing compounds, drugs for the treatment of obesity and modulators or stimulators of the adrenergic system via alpha 1 and alpha 2 as well as beta 1, beta 2 and beta 3 receptor
• a further subject of the invention is a process for the preparation of a compound of general formula (I),
• R 1 to R 7 may have the abovementioned meanings, a compound of the general formula (II) (H) wherein
• R 3 and R 4 may have the abovementioned meaning, by means of a chlorinating agent in a compound of formula (III)
• R 2 , R 3 and R 4 may have the abovementioned meanings, with a compound of the formula (VIa) or (VIb)
• R 1 , R 5 , R 6 and R 7 may have the meanings given above, wherein preferably R 8 is hydrogen or optionally substituted d-do-alkyl! and preferably R 9 is hydrogen or a radical selected from the group consisting of optionally substituted d-Cio-alkyl, QrC ⁇ -cycloalkyl, heterocyclyl, aryl and heteroaryl.
• Alkyl groups and alkyl groups which are part of other groups are, unless stated otherwise, branched and unbranched alkyl groups having 1 to 10 carbon atoms, preference being given to groups having 1 to 6 carbon atoms. Particularly preferred are alkyl groups having 1 to 4 carbon atoms, especially those having 1 or 2 carbon atoms. Examples include: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
• propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl include all of the possible isomeric forms.
• propyl comprises the two isomeric radicals n-propyl and isopropyl
• alkyl groups it is optionally possible for one or more hydrogen atoms to be replaced by other radicals.
• these alkyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
• the substituents are preferably fluorine or chlorine. Particularly preferred is the substituent fluorine. If appropriate, all hydrogen atoms of the alkyl group may also be replaced.
• alkyl groups optionally one or more hydrogen atoms, for example by OH, NO 2 , CN or an optionally substituted radical selected from the group consisting of -O- (C 1 -C 5 -alkyl), preferably methoxy or ethoxy, -O-
• Amine radical preferably methylamine, benzylamine, phenylamine or heteroarylamine, saturated or unsaturated bicyclic ring systems, preferably benzimidazolyl and C 3 -C 8 cycloalkyl, preferably cyclohexyl or cyclopropyl, to be replaced.
• alkenyl groups and alkenyl groups which are part of other groups branched and unbranched alkyl groups having 1 to 10 carbon atoms are preferably 1 to 6, more preferably 1 to 4 carbon atoms containing at least one carbon-carbon double bond. Examples include: ethenyl, propenyl, methylpropenyl, butenyl, pentenyl, hexenyl, heptenyl, methyl heptenyl, octenyl, nonenyl and decenyl.
• alkenyl groups optionally one or more hydrogen atoms may be replaced by other groups.
• these alkenyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
• the substituents are preferably fluorine or chlorine. Particularly preferred is the substituent fluorine. If appropriate, all hydrogen atoms of the alkenyl group may also be replaced.
• alkynyl groups and alkynyl groups which are part of other groups branched and unbranched alkyl groups having 1 to 10 carbon atoms are preferably 1 to 6, more preferably 1 to 4 carbon atoms containing at least one carbon-carbon triple bond.
• branched and unbranched alkyl groups having 1 to 10 carbon atoms are preferably 1 to 6, more preferably 1 to 4 carbon atoms containing at least one carbon-carbon triple bond.
• branched and unbranched alkyl groups having 1 to 10 carbon atoms are preferably 1 to 6, more preferably 1 to 4 carbon atoms containing at least one carbon-carbon triple bond.
• ethynyl, Propinyi, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl are examples of the alkynyl groups and alkynyl groups which are part of other groups.
• alkynyl optionally one or more hydrogen atoms may be replaced by other radicals.
• these alkynyl groups may be substituted by the halogen atoms fluorine, chlorine, bromine or iodine.
• the substituents are preferably fluorine or chlorine. Particularly preferred is the substituent fluorine.
• all hydrogen atoms of the alkynyl group may also be replaced.
• aryl is an aromatic ring system having 6 to 18 carbon atoms, preferably 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, more preferably phenyl, which may be optionally substituted and may preferably carry one or more of the following substituents: OH, NO 2 , CN, -OCHF 2 , -OCF 3 , -NH 2 , -NH-alkyl, -N (alkyl) -alkyl, -NH-aryl, -N (alkyl) -aryl, -NHCO-alkyl, -NHCO-aryl, -N (alkyl) -CO-alkyl, -N (alkyl) -CO-aryl, -NHSO 2 -alkyl, -NHSO 2 -N (alkyl) 2 , -NHSO 2 -aryl, -N ( Alkyl) -SO 2 alkyl, -N (alkyl) -SO 2
• Heteroaryl radicals are to be understood as meaning 5- to 10-membered mono- or bicyclic heteroaryl rings in which one to three carbon atoms in each case can be replaced by a heteroatom selected from the group oxygen, nitrogen or sulfur.
• Examples which may be mentioned are furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazole, isoxazole, thiazole, thiadiazole, oxadiazole, where any of the abovementioned heterocycles may be further annelated to a benzene ring can be, like For example, benzimidazole, and wherein these heterocycles may optionally be substituted and may preferably carry one or more of the following substituents: OH, N0 2 , CN, -NH 2 , -NH-alkyl
• Cycloalkyl radicals are saturated or unsaturated cycloalkyl radicals having 3 to 8 carbon atoms, such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, where any of the abovementioned cycloalkyl radicals is optionally further may bear one or more substituents or may be fused to a benzene ring.
• heterocycloalkyl or heterocyclyl radicals unless otherwise specified in the definitions, 5, 6 or 7-membered, saturated or unsaturated heterocycles which may contain nitrogen, oxygen or sulfur as heteroatoms, such as tetrahydrofuran, tetrahydrof uranone, ⁇ -butyrolactone, ⁇ -pyran, ⁇ -pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, Piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepane, oxazine, tetrahydrooxazinyl, isothi
• the compounds of the above general formula (I) which contain a residue cleavable in vivo represent so-called prodrugs, and compounds of the general formula my formula I, which contain two in vivo cleavable residues, so-called double prodrugs.
• a group which can be converted into a carboxy group in vivo is, for example, an ester of the formula -CO 2 R 11 , where
• R 11 hydroxymethyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkenyl, heterocycloalkyl, dC 3 alkoxycarbonyl, 1,3-dihydro-3-oxo-1-isobenzofuranol, -C (-alkyl) (-alkyl) -OC (0) Alkyl, -CHC (O) NH (-alkyl), -CHC (O) N (-alkyl) (-alkyl), -alkyl, preferably C 1 -C 6 -alkyl, particularly preferably methyl, ethyl, n-propyl, iso- propyl, n-butyl, n-pentyl or n-hexyl,
• Cycloalkyl preferably C 1 -C 6 -cycloalkyl, particularly preferably cyclohexyl, - (C 1 -C 3 -alkyl) -aryl, preferably (C 1 -C 3 -alkyl) -phenyl, more preferably benzyl, -CHC (O) N (-alkyl) (-alkyl) , preferably -CHC (O) N (-C 1 -C 3 -alkyl) (-dC 3 -alkyl), more preferably -CHC (O) N (CH 3 ) 2 ,
• -CH (-alkyl) OC (O) -alkyl preferably -CH (-CH 3 ) OC (O) (--C 1 -C 6 -alkyl), more preferably -CH (-CH 3 ) OC (O) -methyl , -CH (-CH 3 ) OC (O) -ethyl, -CH (-CH 3 ) OC (O) -n-propyl, -CH (-CH 3 ) OC (O) -n-butyl or -CH ( -CH 3 ) OC (0) -t-butyl, or -CH 2 OC (O) -alkyl, preferably -CH 2 OC (O) (--CrC 6 -alkyl), more preferably -CH 2 OC (0) - Methyl, -CH 2 OC (O) -ethyl, -CH 2 OC (O) -n-propyl, -CH 2
• a group which can be converted into a sulfonamide or amino group in vivo is one of the following groups:
• C0-alkyl preferably Ci-Cg-alkoxycarbonyl, particularly preferably methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyl-oxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl, Cyclohexyloxycar - bonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl or n-nonyloxycarbonyl,
• -C (0) heteroaryl preferably pyridinoyl or nicotinoyl or -C (O) -alkyl, preferably -C (O) (-dC 6 -alkyl), more preferably 2-methylsulfonylethoxycarbonyl, 2- (2-ethoxy) -ethoxycarbonyl-.
• the halogen is generally fluorine, chlorine, bromine or iodine, preferably chlorine or fluorine, especially preferably fluorine.
• the compounds according to the invention can be in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, prodrugs, double prodrugs and in the form of the tautomers, salts, solvates and hydrates and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids -
• acid addition salts with hydrohalic acids for example hydrochloric or hydrobromic acid, or organic acids such as oxalic, fumaric, diglycol, formic, malic, benzoic, benzenesulfone, camphorsulfone, acetic, ethanesulfone, glutam -, maleic, almond, lactic, phosphoric, nitric, sulfuric, succinic, para-toluenesulfonic, trifluoroacetic, tartaric, citric or methanesulfonic acid present.
• hydrohalic acids for example hydrochloric or hydro
• novel compounds of the formula I thus obtained if they contain a carboxy group or another acidic group, can then, if desired, subsequently be converted into their salts with inorganic or organic bases, in particular for the pharmaceutical application into their physiologically tolerated salts.
• suitable bases are sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
• the compounds of general formula I which are obtained in racemates can be converted into their optical systems by methods known per se (see Allinger NL and Eliel E. L in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971)
• Antipodes and compounds of general formula I having at least two asymmetric carbon atoms due to their physical chemical differences can be separated into their diastereomers according to methods known per se, for example by chromatography and / or fractional crystallization, which, if they are obtained in racemic form, can then be separated into the enantiomers as mentioned above.
• the enantiomer separation is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reacting with a, with the racemic compound, salts or derivatives such.
• Particularly common optically active acids are e.g.
• the D and L forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid.
• optically active alcohol for example, (+) - or (-) - menthol and as an optically active acyl radical in amides, for example, the (+) - or (-) - Menthyloxycarbonylrest into consideration.
• the substituent R 1 may optionally be substituted aryl or heteroaryl, preferably substituted phenyl. Most preferably, the substituent R 1 is phenyl.
• the substituent R 2 may be a heteroaryl or heterocyclyl which is monosubstituted or polysubstituted by R 10 , where R 2 contains at least one nitrogen atom. Particularly preferred is a singly or multiply substituted with R 10 triazole, a mono- or polysubstituted with R 10 substituted 1, 4-dioxo-3,4-dihydro-1 H-phthalazin, a mono- or polysubstituted with R 0 substituted 2-oxoimidazolidin, a benzimidazole which is monosubstituted or polysubstituted by R 10 or an imidazole which is monosubstituted or polysubstituted by R 10 .
• R 2 is a monosubstituted with R 10 1 H- [1, 2,3] triazol-1-yl, a monosubstituted with R 10th 1, 4-dioxo-3,4-dihydro-1H-phthalazin-2-yl, a 2-oxo-imidazolidine monosubstituted with R 10 1-yl, a monosubstituted with R 10 benzimidazol-1-yl or a monosubstituted with R 10 imidazol-1-yl.
• the substituents R 3 and R 4 can independently of one another be hydrogen or an optionally substituted radical selected from the group consisting of C 3 -C 6 -cycloalkyl or C 1 -C -alkyl, preferably C 1 -C 5 -alkyl, or R 3 and R 4 together represent a 2- to 7-membered alkylene bridge, preferably a 2- to 5-membered alkylene bridge, in particular an ethylene bridge.
• R 3 or R 4 is preferably substituted by -CC 3 alkyl.
• R 3 is methyl.
• R 4 is methyl.
• the substituents R 5 , R 6 and R 7 can independently of one another be hydrogen or a radical selected from the group consisting of halogen, cyano, -NR 8 CO- (C 1 -C 8 -alkyl), -NR 8 CO-aryl, -NR 8 S0 2 - (C 1 -C 5 -alkyl), -NR 8 S0 2 -aryl, -C0 2 R 8 , -SO 2 R 8 , -CONHR 8 , -SO 2 NHR 8 , -OR 8 , optionally substituted C 3 -C 6 -cycloalkyl and optionally substituted C 1 -C 10 -alkyl, preferably hydrogen, halogen, cyano, methoxy, methanesulfonylamino, methanesulfonyl, difluoromethoxy, trifluoromethoxy, difluoromethyl or trifluoromethyl, in particular hydrogen, fluorine, chlorine or cyano.
• a very particularly preferred meaning of the substituents R 5 , R 6 and R 7 is hydrogen.
• the substituent R 8 may be hydrogen or Ci-Cs-alkyl, preferably methyl.
• the substituent R 9 may be hydrogen, optionally substituted aryl or optionally substituted heteroaryl, preferably optionally substituted phenyl, pyridyl or thiophenyl.
• the substituent R 10 can be OH, NO 2 , CN, -OCHF 2 , -OCF 3 , -NH 2 ,, -NH-alkyl, -N (-alkyl) -alkyl, -NH-aryl, -N (-alkyl) -Aryl, -NHCO-alkyl, -NHCO-aryl, -N (-alkyl) CO-alkyl, -N (-alkyl) CO-aryl, -NHSO 2 -alkyl, -NHSO 2 -aryl, -N (-alkyl ) S0 2 -alkyl, -N (-alkyl) - SO 2 -Al, -CO 2 alkyl, -SO 2 alkyl, -SO 2 aryl, -CONH alkyl, -CONH aryl, -CON (alkyl) alkyl, -CON (alkyl) aryl , -SO
• R 10 is -OH, -NO 2) -CN, -NH 2 , -I, -N (CH 3 ) 2 , -NHCO 2 CH 3 , -NHSO 2 CH 3 , -SO 2 N (CH 3 ) 2, -CO 2 H, benzyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, -CONHOH, tetrazol-5-yl, pyridin-4-yl, pyridin-2-yl, 6-methoxypyridin-3-yl, phenyl, 4-hydroxyphenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-aminophenyl, 4-nitrophenyl, thiophen-2-yl, 5-methyl-thiophen-2-yl, 3,5-dimethyl-isoxazol-4-yl or 1-acetyl-2-amino propenyl.
• the compounds according to the invention can be prepared by the synthesis processes described below, where the formulas (I) to (VI) and the substituents of the general formulas R 1 to R 7 have the meanings given above. These methods are to be understood as an explanation of the invention without limiting the same to their subject matter.
• the reaction mixture was stirred for about 48 h at room temperature and then poured into 450 ml of ice-water / ethyl acetate 2: 1.
• the phases were separated and the aqueous phase extracted about three times with 100 mL of ethyl acetate.
• the combined organic phases were washed about five times with 100 ml of water, washed with about 100 ml of saturated, aqueous sodium chloride solution, dried and freed from the solvent.
• the residue was purified by flash column chromatography.
• racemic starting materials starting from racemic starting materials, racemic products are obtained and, starting from enantiomerically pure compounds, enantiomerically pure products are obtained.
• a final racemic compound may be separated into the two enantiomers by, for example, chiral column chromatography or recrystallization with appropriate chiral counterions.
• novel compounds of the general formula (I) can be synthesized in analogy to the following synthesis examples. These examples are to be understood as merely a walkthrough to further explain the invention without limiting it to its subject matter.
• reaction mixture was freed of solvent on a rotary evaporator and dissolved in about 100 ml of ethyl acetate, washed about three times with 30 ml of saturated aqueous sodium bicarbonate solution, dried over sodium sulphate and freed from the solvent on a rotary evaporator. This gave 0.917 g (2.73 mmol, 46%) of N- [3- (2-ethoxy-2-hydroxyacetyl) phenyl] benzenesulfonamide as a yellow solid.
• the aqueous phase was separated from the organic phase and extracted twice with 50 mL of ethyl acetate.
• the combined organic phases were washed with 20 ml of saturated, aqueous sodium chloride solution, dried over magnesium sulfate and freed from the solvent on a rotary evaporator.
• the residue was purified by flash column chromatography [methylene chloride / methanol / ammonia (90: 10: 1)].
• the reaction mixture was cooled to room temperature and then poured into 20 mL dichloromethane and 20 mL water. The phases were separated, the organic phase washed twice with 20 ml of water, dried over magnesium sulfate and freed from the solvent on a rotary evaporator. The residue was purified by flash column chromatography [methylene chloride / methanol (100: 0 ⁇ 75:25)].
• Example 38 4-tetrazolylphenylboronic acid (Organic Letters 6 (2004) 19, 3265-3268)
• Example 14 4-tetrazolylphenylboronic acid (Organic Letters 6 (2004) 19, 3265-3268)
• reaction mixture was stirred for 1 h at 0 ° C and 3.00 g (16.6 mmol) of (3-chloro-1, 1-dimethyl-propyl) -carbaminklare tert-butyl ester and 0.62 g (1 , 67 mmol) tetrabutylammonium iodide was added.
• the reaction mixture was stirred for 48 h at room temperature and then poured into 500 ml of ice water / ethyl acetate 2: 1. The phases were separated and the aqueous phase extracted three times with 150 mL of ethyl acetate.
• Example 37 Benzimidazole-5-carboxylic acid ethyl ester Synthesis of 3-r4- (4-Hydroxy-phenyl-4-imidazol-1-yl-1,1-dimethyl-propylamine (the amine component for the last step of the synthesis of Example 7)
• Examples 17, 32, 34 and 35 were synthesized analogously to the described synthesis of Example 8. Thereto, instead of N- [3- (2- ⁇ 3- [4- (4-nitrophenyl) -imidazol-1-yl] -1,1-dimethyl-propylamino ⁇ -1-hydroxyethyl) -phenyl] -benzenesulfonamide forlgende
• Example 17 4- (1 - ⁇ 3- [2- (3-Benzenesulfonylamino-phenyl) -2-hydroxy-ethylamino] -3-methyl-butyl ⁇ -1 H -imidazol-4-yl) -benzoic acid benzyl ester (Example 16)
• Example 32 N- [3- (2- ⁇ 1,1-Dimethyl-3- [3- (4-nitro-phenyl) -2-oxo-imidazolidin-1-yl] -propylamino ⁇ -1 -hydroxy-ethyl) -phenyl] -benzenesulfonamide (Example 30)
• Example 34 N- [3- (2- ⁇ 3- [4- (3,5-Dimethyl-isoxazol-4-yl) -imidazol-1-yl] -1, 1-dimethyl-propylamino ⁇ -1-hydroxy -ethyl) -phenyl] -benz
• Example 35 N- [3- (2- ⁇ 1,1-Dimethyl-3- [4- (4-nitro-phenyl) -imidazol-1-yl] -propylamino ⁇ -1-hydroxy-ethyl) -phenyl] benzenesulfonamide (Example 4)
• the (R) and (S) -enantiomers of the examples can be obtained from the racemate, for example, by chiral HPLC (e.g., column: Chirobiotic T, 250 x 4.6 mm from Astec).
• HPLC chiral HPLC
• methanol with 0.05% triethylamine and 0.05% acetic acid (mobile phase A) in acetonitrile can be used.
• Silica gel with a particle size of 5 ⁇ m, to which the glycoprotein teicoplanin is covalently bound can be used as column material.
• Example 8 (30% solvent A in acetonitrile):
• Retention time [(R) -N- [3- (2- ⁇ 3- [4-amino-phenyl) -imidazol-1-yl] -1, 1-dimethyl-propylamino ⁇ -1-hydroxy-ethyl) -phenyl] -benzenesulfonamide] 22.4 min
• retention time [(S) -N- [3- (2- ⁇ 3- [4- (4-Amino-phenyl) -imidazol-1-yl] -1, 1 -dimethyl-propylamino ⁇ -1-hydroxy-ethyl) -phenyl] -benzenesulfonamide] 25.1 min.
• Example 17 (30% solvent A in acetonitrile)
• Example 28 (50% solvent A in acetonitrile)
• the compounds of the general formula (I) are distinguished by a variety of possible uses in the therapeutic field.
• Beta-3 agonists in particular of selective beta-3 agonists play a role.
• Such diseases include, for example:
• Atherosclerosis, cholangitis, gallbladder disease, chronic cystitis, chronic cystitis; chronic prostatitis, cystospasm, depression, duodenal ulcer, duodenitis, dysmenorrhoea, increased intraocular pressure and glaucoma, enteritis, esophagitis, gastric ulcer, gastritis, gastrointestinal disorders caused by contraction (s) of smooth muscle, gastrointestinal disorders including gastric ulcer, Gastrointestinal ulcers, gastrointestinal ulcers, glaucoma, glucosuria, hyperanakinesia, hypercholesterolemia, hyperglycemia, hyperlipidemia, arterial hypertension, hypertriglyceridemia, insulin resistance, intestinal ulceration or small bowel ulcers (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis rectal inflammation), irritable colon and other diseases with decreased intestinal motility, depression, melancholia, melancholia, pollakiuria, frequent urinary urgency, neurogenic
• beta-3-agonists of the invention for the treatment of obesity, insulin resistance, diabetes mellitus type 2, Haminkontenenz, Irritable colon and other diseases with decreased intestinal motility or depression, especially for the treatment of diabetes and obesity.
• the activity of the beta-3 agonists can be determined, for example, in a lipolysis test.
• the test method can be performed as described below:
• Adipocytes were isolated from ex vivo adipose tissue by modification of a Rodbell method (Rodbell, M. Metabolism of isolated fat cells .I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239: 375-380, 1964). Cut out fatty tissue was cut into small pieces and mixed with 1 mg / ml collagenase in Krebs Ringer buffer (KBR) containing 6 mM glucose and 2% albumin by gentle shaking for 30-40 minutes at 37 ° C. The cells were filtered through a gauze, washed twice with KRB and centrifuged 50-150 g each for 5 min.
• KBR Krebs Ringer buffer
• Glycerol is phosphorylated by ATP via glycerol kinase.
• the resulting glycerol-1-phosphate is oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate and hydrogen peroxide.
• a quinoneimine dye is formed.
• the dye shows an absorption maximum at 540 nm. The absorption is directly proportional to the glycerol concentration in the samples.
• novel compounds can be used for the prevention, short-term or long-term treatment of the abovementioned diseases, also in combination with other active substances which are used for the same indications.
• active substances which are used for the same indications.
• antidiabetics such as metformin, sulfonylureas (eg glibenclamide, tolbutamide, glimepiride), nateglinides, repaglinide, thiazolidinediones (eg rosiglitazone, pioglitazone), PPAR-gamma agonists (eg Gl 262570), alpha-glucosidase inhibitors (eg acarbose , Voglibose), alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogs (eg exendin-4) or amylin.
• antidiabetics such as metformin, sulfonylureas (eg gli
• inhibitors of protein tyrosine phosphatase 1 substances that influence a deregulated glucose production in the liver, such as inhibitors of glucose-6-phosphatase, or fructose-1, 6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase, the Glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents such as HMG-CoA reductase inhibitors (eg simvastatin, atorvastatin), fibrates (eg Bezafibrate, fenofibrate), nicotinic acid and its derivatives, cholesterol absorption inhibitors such as ezetimibe, bile acid sequestrants such as colestyramine, HDL increasing compounds such as inhibitors of CETP or regulators of ABC1 or drugs for the treatment of obesity such as sibutramine or tetrahydrolipstatin
• a combination with drugs for influencing hypertension such as e.g. All antagonists or ACE inhibitors, diuretics, ß-blockers, as well as other modulators of the adrenergic system or combinations thereof.
• drugs for influencing hypertension such as e.g. All antagonists or ACE inhibitors, diuretics, ß-blockers, as well as other modulators of the adrenergic system or combinations thereof.
• combinations with stimulators of the adrenergic system via alpha 1 and alpha 2 as well as beta 1, beta 2 and beta 3 receptors are particularly suitable.
• the compounds of the general formula (I) can be used alone or in combination with other active compounds according to the invention, if appropriate also in combination with other pharmacologically active substances.
• Suitable application forms are, for example, tablets, capsules, suppositories, solutions, in particular solutions for injection (s.c., i.V., i.m.) and infusion, juices, emulsions or dispersible powders.
• the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, i. in amounts sufficient to reach the dosage range given below.
• the said doses may, if necessary, be given several times a day.
• Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known auxiliaries, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or means for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
• auxiliaries for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or means for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
• Coated tablets may accordingly be obtained by coating cores produced analogously to the tablets with agents normally used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or Sugar, to be produced.
• the core can also consist of several layers.
• the dragee sheath to achieve a depot effect of several layers may consist of the above mentioned in the tablets excipients can be used.
• Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, as well as a taste-improving agent, e.g. Flavorings such as vanillin or orange extract. They may also contain suspending aids or thickening agents, such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
• a sweetener such as saccharin, cyclamate, glycerol or sugar
• a taste-improving agent e.g. Flavorings such as vanillin or orange extract.
• suspending aids or thickening agents such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
• Injection and infusion solutions are prepared in a conventional manner, e.g. with the addition of isotonic agents, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally with the use of emulsifiers and / or dispersants, wherein, for example, when using water as a diluent organic solvents may optionally be used as solubilizers or Hilfleriastoff , manufactured and filled into injection vials or ampoules or infusion bottles.
• isotonic agents e.g. with the addition of isotonic agents, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally with the use of emulsifiers and / or dispersants, wherein, for example, when using water as a diluent organic solvents may optionally be used
• the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
• inert carriers such as lactose or sorbitol
• Suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives.
• auxiliaries for example, water, pharmaceutically acceptable organic solvents such as paraffins (eg petroleum fractions), oils of vegetable origin (eg peanut or sesame oil), mono- or polyfunctional alcohols (eg ethanol or glycerol), excipients such as natural minerals (eg kaolin, Volume- earth, talc, chalk) synthetic minerals (eg fumed silica and silicates), sugars (eg, cane, milk and glucose), emulsifiers (eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (eg magnesium stearate, talc, stearic acid and sodium lauryl sulfate).
• paraffins eg petroleum fractions
• oils of vegetable origin eg peanut or sesame oil
• mono- or polyfunctional alcohols eg ethanol or glycerol
• excipients such as natural minerals (eg kaolin, Volume- earth, talc, chalk) synthetic
• the application is carried out in a customary manner, preferably orally or transdermally, in particular orally.
• the tablets may also contain additives other than those mentioned.
• Sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin, and the like.
• lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for tableting.
• the active ingredients may be added to the abovementioned excipients with different flavor enhancers or dyes.
• solutions of the active ingredients may be employed using suitable liquid carrier materials.
• the dosage for intravenous use is 1 - 1000 mg per hour, preferably between 5 - 500 mg per hour.
• Active ingredient 100 mg lactose 140 mg corn starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg
• the finely ground active substance, lactose and part of the corn starch are mixed together.
• the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried.
• the granules, the remainder of the corn starch and the magnesium stearate are sieved and mixed together.
• the mixture is compressed into tablets of suitable shape and size.
• Cellulose and polyvinylpyrrolidone are mixed together, the mixture screened and processed with the remainder of the corn starch and water to a granulate, which is dried and sieved. To this is added the sodium carboxymethyl starch and the magnesium stearate, mixed and pressed the mixture into tablets of suitable size.
• the active ingredient is dissolved in water at its own pH or optionally at pH 5.5-6.5 and treated with sodium chloride as isotonan.
• the resulting solution is filtered pyrogen-free and the filtrate filled under aseptic conditions in ampoules, which are then sterilized and sealed.
• the vials contain 5 mg, 25 mg and 50 mg active ingredient.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Child & Adolescent Psychology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)
• Nutrition Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34967644

Family Applications (1)

Country Status (20)

Families Citing this family (10)

Family Cites Families (29)

• 2004
  • 2004-04-30 DE DE102004021779A patent/DE102004021779A1/de not_active Withdrawn
• 2005
  • 2005-04-23 AU AU2005240733A patent/AU2005240733A1/en not_active Abandoned
  • 2005-04-23 CN CNA2005800223032A patent/CN101094837A/zh active Pending
  • 2005-04-23 JP JP2007509946A patent/JP4662979B2/ja not_active Expired - Fee Related
  • 2005-04-23 KR KR1020067025276A patent/KR20070026551A/ko not_active Application Discontinuation
  • 2005-04-23 EA EA200601845A patent/EA200601845A1/ru unknown
  • 2005-04-23 WO PCT/EP2005/004385 patent/WO2005108373A1/de active Application Filing
  • 2005-04-23 CA CA002564980A patent/CA2564980A1/en not_active Abandoned
  • 2005-04-23 MX MXPA06012534A patent/MXPA06012534A/es not_active Application Discontinuation
  • 2005-04-23 BR BRPI0510514-5A patent/BRPI0510514A/pt not_active IP Right Cessation
  • 2005-04-23 EP EP05742866A patent/EP1781620A1/de not_active Withdrawn
  • 2005-04-28 PE PE2005000478A patent/PE20060260A1/es not_active Application Discontinuation
  • 2005-04-29 UY UY28879A patent/UY28879A1/es not_active Application Discontinuation
  • 2005-04-29 TW TW094113955A patent/TW200538103A/zh unknown
  • 2005-04-29 US US11/118,295 patent/US20050245526A1/en not_active Abandoned
  • 2005-04-29 AR ARP050101703A patent/AR050153A1/es not_active Application Discontinuation
• 2006
  • 2006-09-20 ZA ZA200607872A patent/ZA200607872B/xx unknown
  • 2006-10-26 IL IL178887A patent/IL178887A0/en unknown
  • 2006-10-30 EC EC2006006964A patent/ECSP066964A/es unknown
  • 2006-11-03 NO NO20065073A patent/NO20065073L/no not_active Application Discontinuation
• 2008
  • 2008-05-01 US US12/113,780 patent/US7977334B2/en active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events